NCT07545473 · RECRUITING
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
This study tests whether a special eye-scanning camera can detect signs of Alzheimer's and other brain diseases by photographing the retina using multiple wavelengths of light. It is not a drug trial — it is a diagnostic imaging study. Researchers want to know if this non-invasive eye scan can pick up amyloid protein deposits and other disease markers. Phase NA means this is a feasibility and diagnostic accuracy study, not a treatment trial.
You may qualify if
- Aged over 30 years.
- Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited).
- With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests.
- Have a minimum best corrected visual acuity level of 6/60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy.
- Be willing to participate in the study and attend the Centre for Eye Research Australia.
- Be accompanied by a friend or family member.
You're excluded if
- Inability to provide informed consent
- Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)
- Known contraindication to pharmacological pupil dilation
- Any condition that, in the investigator's opinion, would compromise participant safety or image quality
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-22